{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:26:57Z","timestamp":1792520817593,"version":"4.5.0"},"reference-count":35,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T00:00:00Z","timestamp":1518825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Epigenetic events and genetic alterations under the control of the tumor microenvironment potentially mediate tumor induced angiogenesis involved in soft tissue sarcoma (STS) metastasis. Addition of antiangiogenic agent, such as bevacizumab, to standard chemotherapy in treatment of sarcoma has been studied in clinical trials, but most of the findings have not supported its use. We hypothesized the existence of an epigenetically mediated \u201cangiogenic switch\u201d, and the tumor microenvironment, prevents bevacizumab from truly blocking angiogenesis. The addition of valproic acid (VPA), a weak histone deacetylase inhibitor, and bevacizumab, a monoclonal antibody against vascular endothelial growth factor, together with the cytotoxic effects of gemcitabine and docetaxel, may enhance responses and alter chemoresistance. This was designed as a phase I\/II trial with primary endpoints including safety of the treatment combination and tumor response. Unresectable or metastatic sarcoma patients &gt;18 years of age, irrespective of number of prior treatments, received VPA 40 mg\/kg orally for 5 days prior to day 1, bevacizumab at 15 mg\/kg IV on day 1, gemcitabine 900 mg\/m2 (day 1, day 8), and docetaxel 75 mg\/m2 (day 8). Cycles were of 28 day duration. Bevacizumab and VPA were continued as maintenance after 6 cycles, until disease progression. A standard 3 + 3 phase I dose de-escalation design was utilized to evaluate safety. Gain of function p53 gene mutation testing was performed on available archival tissue specimens. A total of 46 patients (30 female, 16 male) with median age of 60 (range 24\u201381) years were enrolled; 34 (73.9%) patients received prior chemotherapy, 14 (30%) of which received prior gemcitabine and docetaxel. Patients received a median of 5.5 cycles (range 0\u201324 of treatment (min 0, one patient died prior to completing the first cycle; max: 24, one patient received 6 cycles and 18 maintenance cycles before progressing). Seventeen patients underwent dose reduction, of which VPA was reduced in 6 patients. Forty-one patients were evaluable for response. There was a confirmed complete response in 1 (epithelioid sarcoma), and a partial response (PR) in 6 (1 carcinosarcoma, 2 extrauterine leiomyosarcoma (LMS), 2 undifferentiated pleomorphic sarcoma, and 1 uterine LMS) patients. Stable disease (SD) was seen in 21 patients for at least 2 months. One subject with prior gemcitabine and docetaxel had PR, and 7 had SD. Median progression-free survival (PFS) was 5.7 months (95% CI: 2.1\u20138.0), and overall survival (OS) was 12.9 months (95% CI: 8.3\u201314.5). Three patients died due to tumor progression while on the study. The combination of VPA, bevacizumab, gemcitabine, and docetaxel appears to be moderately safe and well tolerated. Given that there are very limited options for patients with relapsed refractory STS, this drug combination may be an important therapy to consider. This combination treatment deserves further investigation in epithelioid and carcinosarcoma subtypes.<\/jats:p>","DOI":"10.3390\/cancers10020053","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T03:54:22Z","timestamp":1519098862000},"page":"53","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A Phase I\/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1185-5448","authenticated-orcid":false,"given":"Varun","family":"Monga","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3518-0411","authenticated-orcid":false,"given":"Umang","family":"Swami","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munir","family":"Tanas","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Bossler","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Mott","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Iowa College of Public Health & Holden Comprehensive Cancer Center, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Milhem","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor Angiogenesis: Therapeutic Implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00432-003-0504-0","article-title":"Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma","volume":"130","author":"Potti","year":"2004","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s004320050036","article-title":"Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours","volume":"126","author":"Kuhnen","year":"2000","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7135","DOI":"10.1200\/JCO.2005.16.139","article-title":"Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas","volume":"23","author":"Anderson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/annonc\/mdr299","article-title":"Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: The Axtell regimen","volume":"23","author":"Verschraegen","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mds237","article-title":"An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas","volume":"24","author":"Agulnik","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1158\/0008-5472.CAN-05-1187","article-title":"CpG island methylation of DNA damage response genes in advanced ovarian cancer","volume":"65","author":"Teodoridis","year":"2005","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/sj.bjc.6603024","article-title":"Epigenetics as a mechanism driving polygenic clinical drug resistance","volume":"94","author":"Glasspool","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7","article-title":"Histone deacetylases, transcriptional control, and cancer","volume":"184","author":"Cress","year":"2000","journal-title":"J. Cell. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/PL00000896","article-title":"Histone acetylation and disease","volume":"58","author":"Timmermann","year":"2001","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF03402044","article-title":"Histone acetylation modifiers in the pathogenesis of malignant disease","volume":"6","author":"Mahlknecht","year":"2000","journal-title":"Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.onc.1205108","article-title":"Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling","volume":"21","author":"Deroanne","year":"2002","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/mol.65.3.520","article-title":"Valproic acid inhibits angiogenesis in vitro and in vivo","volume":"65","author":"Michaelis","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1158\/1078-0432.CCR-05-1132","article-title":"Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589","volume":"12","author":"Qian","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/01.RES.0000037983.07158.B1","article-title":"Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis","volume":"91","author":"Rossig","year":"2002","journal-title":"Circ. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJM199601183340308","article-title":"Antiepileptic drugs","volume":"334","author":"Brodie","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","article-title":"A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors","volume":"18","author":"Candelaria","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_23","first-page":"7291","article-title":"Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA","volume":"63","author":"Kim","year":"2003","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-4598-4-22","article-title":"Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study","volume":"4","author":"Cetina","year":"2005","journal-title":"Mol. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2014.58.3781","article-title":"Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: An NRG Oncology\/Gynecologic Oncology Group study","volume":"33","author":"Hensley","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_27","first-page":"395","article-title":"p53 gene mutations and p53 protein expression in human soft tissue sarcomas","volume":"121","author":"Yoo","year":"1997","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_28","first-page":"211","article-title":"p53 gene mutations in soft-tissue sarcomas-correlations with p53 immunohistochemistry and DNA ploidy","volume":"123","author":"Radig","year":"1997","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF03401743","article-title":"Soft tissue sarcomas and p53 mutations","volume":"4","author":"Taubert","year":"1998","journal-title":"Mol. Med."},{"key":"ref_30","first-page":"3655","article-title":"Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression","volume":"60","author":"Zhang","year":"2000","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/annonc\/mdv598","article-title":"TP53 mutational status is predictive of pazopanib response in advanced sarcomas","volume":"27","author":"Koehler","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19257","DOI":"10.3390\/ijms140919257","article-title":"The consequence of oncomorphic TP53 mutations in ovarian cancer","volume":"14","author":"Brachova","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: New functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/pros.10072","article-title":"Complex functions of mutant p53 alleles from human prostate cancer","volume":"51","author":"Shi","year":"2002","journal-title":"Prostate"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/j.gastro.2013.07.049","article-title":"Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor","volume":"145","author":"Murphy","year":"2013","journal-title":"Gastroenterology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/2\/53\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:55:27Z","timestamp":1760194527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/2\/53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,17]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2]]}},"alternative-id":["cancers10020053"],"URL":"https:\/\/doi.org\/10.3390\/cancers10020053","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,17]]}}}